TCT Conference 2024 - Clinical outcomes of early intervention in patients with asymptomatic aortic stenosis (AS) did not impact the composite primary outcome of all cause mortality and unplanned AS related hospitalisation.

Dr Marc Dweck (University of Edinburgh, Edinburgh, UK) joins us in this short interview filmed onsite at TCT Conference to discuss the findings from EVOLVED (NCT03094143; University of Edinburgh).

EVOLVED is a multicenter, prospective, controlled trial, where patients with asymptomatic severe AS were screened across sites to measure high-sensitivity troponin to evaluate risk of left ventricular decompensation. Patients with mid wall fibrosis (heart scarring) are randomized to receive either early surgical intervention or routine care. Participants with no mid-wall fibrosis are randomized to routine care with study follow up, or without study follow up. 208 patients were enrolled in the trial and were followed-up at study completion, which is expected at 2.75 years. 

The primary outcome measure, a composite of the first event of all-cause mortality or unplanned AS-related hospitalisation, was not met. 

Interview Questions:
1.    What is the reasoning behind the trial?
2.    What was the study design and patient population for EVOLVED?
4.    What were the key findings and take-home messages?
5.    What further research is needed, and what are the next steps?

Recorded at TCT Conference in Washington, 2024.

Editors: Yazmin Sadik, Jordan Rance
Video Specialist: David Ben-Harosh, Oliver Miles

Support: This is an independent interview produced by Radcliffe Cardiology.